South Plainfield, NJ – Oct 18, 2010 -- GENEWIZ, Inc., the U.S. leader in Sanger DNA sequencing, announced an expansion of its U.S. DNA sequencing capabilities with the opening of its Boston Laboratory. Located in Cambridge, MA the GENEWIZ lab is fully operational, providing local DNA sequencing with the fastest turnaround for the region’s pharmaceutical, biotechnology, clinical, academic and government institutions. Sample pickup is available through free courier service and on-site drop boxes.
GENEWIZ services offered locally from the Boston GENEWIZ Laboratory include individual tube and high-volume DNA sequencing, primer walking, and sequencing from bacterial colonies, phage supernatant and glycerol stocks. Other GENEWIZ offerings, including gene synthesis,molecular biology and genomic services, at both research and regulatory/GLP levels, are available as usual by contacting GENEWIZ headquarters.
"Our customers gave us a remarkably warm welcome," stated Barbara Frank, GENEWIZ Regional Sales Manager. "Everyone is pleased to save so much research time, while experiencing GENEWIZ's high-quality, convenient DNA sequencing. We hope that researchers will take advantage of our "Enjoy Life" program, with the chance to win a Kindle per month in October, November, and December 2010 and a $10 Amazon gift card per week. Everyone who tries our services here in Boston will receive a free trial coupon."
GENEWIZ, Inc. is a contract research organization (CRO) specializing in DNA-based services including DNA sequencing, gene synthesis, molecular biology, genomic and GLP/CLIA regulatory services. The company leads the industry in US research sequencing and outsourcing partnerships with pharmaceutical, clinical, biotechnology, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held, global enterprise with additional laboratory locations in Washington D.C. Metro, Boston, San Diego, Suzhou, China, and Beijing, China. For more information see www.genewiz.com or call 1-877-436-3949 x3202.